VANCOUVER, BRITISH COLUMBIA--(Marketwire - Sept. 28, 2012) - In accordance with regulatory requirements, Mr. Michael Withrow, the President, CEO, acting CFO and a director of Abattis Bioceuticals Corp. (CNSX:FLU) ("Abattis"), announces that he has recently acquired, directly or indirectly, 6,136,362 common shares of Abattis.
Prior to such acquisition, Mr. Withrow held, directly or indirectly or had control over, 909,600 common shares, 330,000 warrants of Abattis, each of which warrants entitle the holder to acquire one common share in the capital of Abattis. In addition, Mr. Withrow holds an aggregate of 300,000 options to acquire 300,000 common shares of Abattis.
Mr. Withrow currently holds or exercises control or direction over an aggregate of 7,045,962 common shares of Abattis which represent an interest of 38.10% of Abattis' issued and outstanding capital at the date hereof on a non-diluted basis. Assuming the exercise of all warrants and options held by him or over which he has control or direction, Mr. Withrow will hold or exercise control or direction over an aggregate of 7,675,962 common shares of Abattis, which represent an interest of 40.15% of Abattis' issued and outstanding capital at the date hereof, on a partially diluted basis.
The securities acquired by Mr. Withrow referred to above are held for investment purposes only. These investments will be reviewed on a continuing basis and holdings may be increased or decreased in the future.
|21141 80B Avenue
|Langley, BC V2Y 0J5